Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia (INSPIRE)
Immunotherapy Navigated by Serum Presepsin for Infections of the Respiratory Tract: the INSPIRE Double-blind, Randomized, Phase IIa Exploratory Trial.
Sponsor: Hellenic Institute for the Study of Sepsis
Listed as NCT05785442, this PHASE2 trial focuses on Community-acquired Pneumonia and Hospital-acquired Pneumonia and remains completed. Sponsored by Hellenic Institute for the Study of Sepsis, it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2023 — May 2024 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Apr 2023 — Oct 2023 [monthly]
Recruiting PHASE2
First recorded
Mar 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hellenic Institute for the Study of Sepsis
For direct contact, visit the study record on ClinicalTrials.gov .